View Post

Study Identifies Potential Biomarkers for De-escalating Chemotherapy in HER2-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

From: specialtypharmacytimes.com Certain human epidermal growth factor receptor 2 (HER2)-positive breast cancer tumors may be more sensitive to treatment with anti-HER2 therapy alone, potentially eliminating the need for additional chemotherapy, according to a study published in the Journal of the National Cancer Institute. Approximately 1 in 5 patients with breast cancer have high levels of HER2 proteins, according to the …

View Post

Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory AML or Higher Risk MDS

In Clinical Trials by Barbara Jacoby

From: prnewswire.com – Milestone represents the first patient dosed with Precigen’s transformative non-viral UltraCAR-T therapeutic platform that eliminates ex vivo expansion and reduces manufacturing time to fewer than two days following gene transfer Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the …

View Post

Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: GLOBE NEWSWIRE From: yahoo.com 226 patients with metastatic breast cancer have been enrolled in the AIPAC study Combination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with chemotherapy is designed to boost the T-cell immune responses against tumours Read-out of progression-free survival (PFS) primary endpoint expected to occur in Q1 of calendar year 2020 Immutep …

View Post

Prestigious Cancer Centers Johns Hopkins and Moffitt Complete Patient Enrollment in Post Approval Study for MarginProbe®

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: yahoo.com Dune Medical Devices has reached another milestone in their MarginProbe® Post Approval Study (PAS) as Johns Hopkins Hospital and Moffitt Cancer Center complete their patient enrollments for the trial. This PAS, required by the FDA, seeks to substantiate the vast body of data produced since MarginProbe’s original approval, demonstrating its effectiveness at intraoperatively identifying positive …

View Post

Clinical Trial Solutions: Technology Disrupters

In Clinical Trials by Barbara Jacoby

By: A.K. Gupta, Senior VP and Chief Information Officer, UBC From: pharmavoice.com The biopharma industry faces myriad challenges in the pursuit of its mission to bring new treatments to patients in need of cures, chief among them the “Iron Triangle” of time, cost, and quality with respect to clinical research. The cost of conducting clinical trials is escalating, quality remains …

View Post

Q&A: Phase I clinical trials

In Clinical Trials by Barbara Jacoby

By: Devon Carter From: mdanderson.org Phase I clinical trials are the foundation for how we develop new cancer drugs. Typically, they involve only several dozen patients and study a new medicine’s effect on a variety of cancer types. David S. Hong, M.D., sat down with us to explain more about Phase I clinical trials and answer some of patients’ most …

View Post

Clinical Trials at MD Anderson

In Clinical Trials by Barbara Jacoby

From: mdanderson.org As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. Look through our database to find studies for which you may be eligible. What are clinical trials? Clinical trials are research studies in which patients may volunteer to take part. MD Anderson …

View Post

Dr. Anders on Abemaciclib in HR+ Breast Cancer With Brain Metastases

In Clinical Trials by Barbara Jacoby

By: Carey Anders, MD From: onclive.com Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discussed the use of abemaciclib (Verzenio), a selective CDK4/6 inhibitor, in patients with hormone receptor–positive, HER2-negative metastatic brain cancer with brain metastases. In the study, 52 patients were evaluated and had a median of 4 prior systemic therapies. Of the group, 75% …

View Post

Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer

In Clinical Trials by Barbara Jacoby

From: biospace.com Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial. Polyphor today announced the enrollment of the first patient in its FORTRESS clinical trial, the pivotal Phase III study evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer …

View Post

Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands

In Clinical Trials by Barbara Jacoby

Source: Celsion CORP From: globenewswire.com An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range of Solid Tumors with Multiple Localized Heating Sources Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in …